The average treatment effect in the treated hazard ratio among those who received sotrovimab was 0.92 (95% confidence ...

Yale scientists have discovered a promising way to trigger immune responses against certain tumors, using a lupus-related antibody that can slip, undetected, into "cold" tumors and flip on an immune ...

For individuals with dominantly inherited Alzheimer disease (DIAD), long-term treatment with gantenerumab, an anti-amyloid ...

People fully vaccinated against hepatitis B who are not immunocompromised can expect sustained immunity throughout their ...

NEW YORK, March 25, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully hu ...

GSK’s application is underpinned by the positive outcomes from the Phase III MATINEE trial, which demonstrated a significant ...

FairJourney Biologics S.A., global leader in antibody discovery and development, today announced the formation of its ...

The complaint filed in a Seattle court alleges that Genmab, its subsidiary ProfoundBio that was acquired last year, and ...

As AbbVie accuses Genmab of unlawfully using proprietary ADC technology, find out about their collaboration and the dispute ...

A super-resolution microscopy technique offers an unparalleled glimpse into how monoclonal antibodies bind to their targets ...

Harbour BioMed inks collaboration with AstraZeneca to discover and develop next-generation therapeutic antibodies: Shanghai & Rotterdam, The Netherlands Tuesday, March 25, 2025, 1 ...

Cambridge: Harbour BioMed, a global biopharmaceutical company has announced a global strategic collaboration with AstraZeneca ...